Zealand Pharma AS (OCSE:ZEAL)
kr 730 0 (0%) Market Cap: 51.57 Bil Enterprise Value: 43.49 Bil PE Ratio: 0 PB Ratio: 5.83 GF Score: 67/100

Zealand Pharma A/S at Goldman Sachs Healthcare C-Suite Unscripted Conference Transcript

Jan 04, 2024 / 03:10PM GMT
Release Date Price: kr350.8 (+0.46%)
Moderator

Hi, everyone. Thanks for joining us for the next session. I'm pleased that we have Adam Steensberg, who's CEO of Zealand Pharma with us today. Adam, thanks for joining us and making the trip over in person. Maybe just kind of to kick it off, if you wanted to kind of make some high-level introductory comments about Zealand, about the pipeline, about therapeutic focus for some of the people that may be less familiar with the company.

Adam Steensberg Zealand Pharma A;S;President
CEO & Member of the Executive Management

/- -

Absolutely. And thank you for the invitation. Great to be here. So Zealand Pharma is a Danes-based biotech company focused on peptide drug discovery and development. We have a very strong pipeline within obesity, both assets in phase 1 through Phase 3, and together with our partner Boehringer, one of them.

And then we have opportunities in rare diseases and chronic inflammation, so basically leveraging our peptide drug discovery and development skills, which we have been refining, I would say, over 25

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot